# Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing

> **NCT03608865** · PHASE2 · COMPLETED · sponsor: **Yonsei University** · enrollment: 30 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Durvalumab with Tremelimumab

## Key facts

- **NCT ID:** NCT03608865
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-19
- **Primary completion:** 2021-11-24
- **Final completion:** 2021-11-24
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03608865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03608865, "Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03608865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*